ATAI surged approximately +31.72% to $7.06 after Eli Lilly confirmed it will acquire the psychedelic drug developer in a deal valued at up to $3.8 billion. The rally was ignited in premarket trading following a Wednesday evening Bloomberg report that Lilly was in advanced buyout talks, with the official announcement confirming terms Thursday morning.

ABT surged +12.46% during Thursday's regular session after reporting Q2 2026 earnings premarket that beat estimates across key metrics. Adjusted EPS of $1.31 topped the $1.28 consensus, while revenue of $12.59B exceeded the $12.52B forecast, reflecting +13% reported sales growth year-over-year.

CHRN is trading down approximately -13.03% during regular market hours, falling from yesterday's close of $29.63 to around $25.77, giving back nearly half of the prior session's explosive gains. The sell-off follows yesterday's +28.77% surge, which was fueled by ASML's strong earnings and raised 2026 outlook that reignited enthusiasm across AI infrastructure names.

WDC is down -4.71% in regular trading today, compounding yesterday's -8.78% plunge as a memory-sector rout deepens. The selloff is driven by aggressive profit-taking after memory stocks surged Tuesday on IBM's warning that customers were redirecting spending toward servers, storage, and memory chips.

ASTS shares tumbled -9.76% on Thursday, extending an after-hours plunge of approximately -13% that began Wednesday evening after the company announced a $1 billion convertible senior notes offering due 2034. The primary catalyst is the convertible note raise, which spooked investors over potential future share dilution — this marks ASTS's second $1 billion convertible offering in recent months, reigniting concerns about its heavy cash burn and capital needs.

IPAY gained approximately 12% over the trailing 30-day period, rebounding sharply from a June low near $42 to trade above $49. The quarterly trend shows a more moderate gain of roughly 4–5%, reflecting a volatile path marked by a sharp sell-off in early June followed by a powerful recovery.

VXX is an exchange-traded note (ETN) issued by Barclays that tracks the S&P 500 VIX Short-Term Futures Index, providing exposure to a daily rolling blend of first- and second-month VIX futures contracts. The product is structurally designed as a short-term tactical instrument for hedging or speculation, and is not suitable for buy-and-hold strategies due to persistent contango decay that erodes value over time.

Target price: $30 per share, representing a roughly 40-45% gain from recent levels near $21, a round psychological level the ETF has crossed multiple times over the past year. Strongest bullish factor: A sudden spike in equity market volatility — driven by geopolitical shock, recession fears, or a rapid equity sell-off — would directly lift VIX futures prices and propel VIXY higher.

VIXY tracks the S&P 500 VIX Short-Term Futures Index, providing exposure to front-month and next-month VIX futures contracts rather than the spot VIX itself. The ETF holds approximately five assets, primarily Cboe VIX futures contracts alongside cash equivalents and Treasury bills, and carries an expense ratio of 0.85%.

TowneBank shares are trading near $36.10, up approximately 2.8% over the past 30 days, reflecting steady investor confidence in the Virginia-based regional bank. The company completed three strategic bank acquisitions in the past year, adding roughly $3.8 billion in assets and expanding its footprint across the Carolinas.

Maximus shares have declined approximately 5.3% over the last 30 days, closing at $57.97 on July 15, 2026, extending a year-to-date decline of roughly 33%. The company continues to raise earnings guidance for fiscal 2026, now forecasting adjusted EPS between $8.25 and $8.55, supported by AI-driven automation and margin expansion.

Price target in focus: $500 per share — a psychologically significant round number roughly 33% above Ferrari's recent closing price near $375 and just below the stock's 52-week high of $519.10. Strongest bullish factors: Record order backlogs extending into 2027, industry-leading EBITDA margins approaching 39%, disciplined scarcity-driven production, and successful hybrid model adoption now representing over 60% of deliveries.

IQVIA Holdings trades near $207, and the $250 price target represents roughly 21% upside from current levels — a round-number psychological milestone that has not yet been reached, with the 52-week high sitting at $247.05. The strongest bullish factors include a consensus "Strong Buy" analyst rating, a $2 billion share repurchase program, expanding AI capabilities through the IQVIA.ai platform built with NVIDIA, and a record R&D Solutions backlog in high-growth areas like oncology and cell therapy.

Price Target: The $800 level has become a widely discussed milestone for the SPY ETF, representing roughly a 6–7% advance from its recent trading range near $745–$752. Bullish Catalysts: Strong corporate earnings growth, AI-driven productivity gains, and accommodative Federal Reserve policy provide tailwinds that could propel the S&P 500 toward new all-time highs.

IQVIA Holdings (IQV) surged approximately 15.4% over the past 30 days, climbing from $179.17 on June 16 to $206.81 as of the July 15 close. Over the last quarter, the stock has risen roughly 20.3%, extending a broader recovery from its 52-week low of $154.50.

Mastercard shares gained approximately 6.8% over the last 30 days, rising from around $501 to $535, outpacing the broader S&P 500 during the same period. Q1 2026 earnings beat consensus estimates, with adjusted EPS of $4.60 on revenue of $8.4 billion, reflecting 15.8% year-over-year revenue growth and a 13% surge in cross-border volume.

JNJ delivered strong Q2 2026 results with $25.3 billion in sales and raised full-year guidance, supporting steady performance in a diversified healthcare model. MRNA trades at approximately $68 with significant year-to-date gains exceeding 130%, though it faces expected revenue declines ahead of its July 31 earnings report.

Moderna shares surged approximately 55% over the past 30 days, driven by a unanimous FDA advisory committee vote backing its mRNA-based seasonal flu vaccine and a transformative Science Day presentation. The FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 that the benefits of mFLUSIVA (mRNA-1010) outweigh its risks for adults aged 50 and older, with a final regulatory decision expected by August 5, 2026.

Reported Q2 2026 operating revenue of $49.8 billion, up 0.8% year over year. Diluted EPS reached $6.71 and adjusted diluted EPS hit $7.45, exceeding internal outlook.

PNC reported second quarter 2026 net income of $2.1 billion and diluted EPS of $4.81, or $4.85 as adjusted. Revenue reached a record $6.88 billion, up 21% from the prior year.